NASDAQ · BVS
Bioventus Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for BVS: Nov 02, 2026
Bioventus Inc. Class A Common Stock is expected to report earnings on 11/02/2026 after market close. The report will be for the fiscal Quarter ending Sep 2026. According to Zacks Investment Research, based on 2 analysts' forecasts, the consensus EPS forecast for the quarter is $0.17. The reported EPS for the same quarter last year was $0.15.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $0.17 | $0.17 | $0.17 | 2 |
| Dec 2026 | $0.25 | $0.25 | $0.24 | 2 |
| Mar 2027 | $0.13 | $0.13 | $0.13 | 1 |
| Jun 2027 | $0.25 | $0.25 | $0.25 | 1 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Zacks · The Motley Fool · RTTNews · MarketBeat- Zacks · Aug 24, 9:40 AM EDTAre Medical Stocks Lagging Bioventus (BVS) This Year?Here is how Bioventus (BVS) and Amneal Pharmaceuticals (AMRX) have performed compared to their sector so far this year.
- Zacks · Aug 20, 8:46 AM EDT4 Healthcare Stocks to Safeguard Your Portfolio as Fed Plans Rate HikeA rate hike could keep markets volatile, making BVS, CNC, AMRX and CRON healthcare stocks to consider as inflation stays elevated.
- The Motley Fool · Aug 13, 9:17 AM EDTBioventus (BVS) Q2 2026 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo
- Zacks · Aug 7, 9:40 AM EDTIs Bioventus (BVS) Stock Undervalued Right Now?Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
- RTTNews · Aug 6, 4:54 AM EDTBiotech Stocks At 52-Week Highs – BVS, TVTX, ODTX, CRL Climb With Q2 Results, ACRS(RTTNews) – The following biotech stocks reached a 52-week high on August 5, 2026, primarily driven by positive quarterly reports.
- MarketBeat · Aug 5, 10:04 AM EDTBioventus Q2 Earnings Call HighlightsBioventus (NASDAQ:BVS) reported second-quarter 2026 revenue growth of 4% and reiterated its full-year financial outlook, citing double-digit expansion in its Pain Treatments business, continued debt reduction and increased investment in platelet-rich plasma, peripheral nerve stim
- Zacks · Aug 5, 9:00 AM EDTBioventus (BVS) Q2 Earnings Meet EstimatesBioventus (BVS) delivered earnings and revenue surprises of 0.00% and -1.16%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
- RTTNews · Aug 5, 7:49 AM EDTBioventus Inc. Q2 Profit Advances(RTTNews) – Bioventus Inc. (BVS) announced earnings for its second quarter that Increases, from last year
- Zacks · Jul 30, 10:00 AM EDTRelay Therapeutics, Inc. (RLAY) Expected to Beat Earnings Estimates: Should You Buy?Relay Therapeutics (RLAY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Zacks · Jul 29, 10:00 AM EDTBioventus (BVS) to Report Q2 Results: Wall Street Expects Earnings GrowthBioventus (BVS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- RTTNews · Jul 29, 4:21 AM EDTBiotech Stocks At 52-Week Highs – INCY Rises With Q2 Results, PLSE, SI, BVS, LBRX(RTTNews) – The following biotech stocks reached a 52-week high on July 28, 2026, driven by key catalysts including positive quarterly results.
- Zacks · Jul 27, 9:40 AM EDTIs Bioventus (BVS) Stock Outpacing Its Medical Peers This Year?Here is how Bioventus (BVS) and Aveanna Healthcare (AVAH) have performed compared to their sector so far this year.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Financials
Loading fundamental data…
More headlines
More stories for Bioventus Inc. from TradingView. Coverage varies.
Loading related news…
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.